BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bernabéu-Herrero ME, Jiménez-Alcázar M, Anter J, Pinto S, Sánchez Chinchilla D, Garrido S, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol 2015;67:276-86. [PMID: 26163426 DOI: 10.1016/j.molimm.2015.06.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Berra S, Clivio A. Rapid isolation of pure Complement Factor H from serum for functional studies by the use of a monoclonal antibody that discriminates FH from all the other isoforms. Mol Immunol 2016;72:65-73. [PMID: 26972487 DOI: 10.1016/j.molimm.2016.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Józsi M, Schneider AE, Kárpáti É, Sándor N. Complement factor H family proteins in their non-canonical role as modulators of cellular functions. Seminars in Cell & Developmental Biology 2019;85:122-31. [DOI: 10.1016/j.semcdb.2017.12.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
3 Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 2018;18:5-18. [PMID: 28920587 DOI: 10.1038/nri.2017.97] [Cited by in Crossref: 157] [Cited by in F6Publishing: 155] [Article Influence: 31.4] [Reference Citation Analysis]
4 Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017;18:6. [PMID: 28056875 DOI: 10.1186/s12882-016-0420-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
5 Valoti E, Noris M, Perna A, Rurali E, Gherardi G, Breno M, Parvanova Ilieva A, Petrov Iliev I, Bossi A, Trevisan R, Dodesini AR, Ferrari S, Stucchi N, Benigni A, Remuzzi G, Ruggenenti P. Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Front Genet 2019;10:681. [PMID: 31428128 DOI: 10.3389/fgene.2019.00681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016;2016:217-25. [PMID: 27913483 DOI: 10.1182/asheducation-2016.1.217] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
7 van Beek AE, Pouw RB, Brouwer MC, van Mierlo G, Geissler J, Ooijevaar-de Heer P, de Boer M, van Leeuwen K, Rispens T, Wouters D, Kuijpers TW. Factor H-Related (FHR)-1 and FHR-2 Form Homo- and Heterodimers, while FHR-5 Circulates Only As Homodimer in Human Plasma. Front Immunol 2017;8:1328. [PMID: 29093712 DOI: 10.3389/fimmu.2017.01328] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
8 Pouw RB, Brouwer MC, Geissler J, van Herpen LV, Zeerleder SS, Wuillemin WA, Wouters D, Kuijpers TW. Complement Factor H-Related Protein 3 Serum Levels Are Low Compared to Factor H and Mainly Determined by Gene Copy Number Variation in CFHR3. PLoS One 2016;11:e0152164. [PMID: 27007437 DOI: 10.1371/journal.pone.0152164] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
9 Gómez Delgado I, Corvillo F, Nozal P, Arjona E, Madrid Á, Melgosa M, Bravo J, Szilágyi Á, Csuka D, Veszeli N, Prohászka Z, Sánchez-Corral P. Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome. Front Immunol 2021;12:641656. [PMID: 33777036 DOI: 10.3389/fimmu.2021.641656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
11 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
12 Cheng G, Ozgonenel B, Bhambhani K, Kapur G, Smith RJ, Savaşan S. Recurrent Atypical Hemolytic Uremic Syndrome in Children With Acute Lymphoblastic Leukemia Undergoing Maintenance Chemotherapy. J Pediatr Hematol Oncol 2018;40:560-2. [PMID: 28991131 DOI: 10.1097/MPH.0000000000000987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Arjona E, Huerta A, Goicoechea de Jorge E, Rodríguez de Córdoba S. Familial risk of developing atypical hemolytic-uremic syndrome. Blood 2020;136:1558-61. [PMID: 32488248 DOI: 10.1182/blood.2020006931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]
15 Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 2016;12:563-78. [PMID: 27452363 DOI: 10.1038/nrneph.2016.99] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
16 Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol 2020;31:241-56. [PMID: 31980588 DOI: 10.1681/ASN.2019050515] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
17 Yang MM, Sun HY, Meng T, Qiu SH, Zeng QQ, Ng TK, Jiang L, Deng TM, Zeng AN, Wang J, Luo XL. CFH I62V as a Putative Genetic Marker for Posner-Schlossman Syndrome. Front Immunol 2021;12:608723. [PMID: 33643312 DOI: 10.3389/fimmu.2021.608723] [Reference Citation Analysis]
18 Sánchez-Corral P, Pouw RB, López-Trascasa M, Józsi M. Self-Damage Caused by Dysregulation of the Complement Alternative Pathway: Relevance of the Factor H Protein Family. Front Immunol 2018;9:1607. [PMID: 30050540 DOI: 10.3389/fimmu.2018.01607] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
19 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]
20 van Beek AE, Kamp A, Kruithof S, Nieuwenhuys EJ, Wouters D, Jongerius I, Rispens T, Kuijpers TW, Gelderman KA. Reference Intervals of Factor H and Factor H-Related Proteins in Healthy Children. Front Immunol 2018;9:1727. [PMID: 30116238 DOI: 10.3389/fimmu.2018.01727] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Gómez Delgado I, Sánchez-Corral P. Contribution of functional and quantitative genetic variants of Complement Factor H and Factor H-Related (FHR) proteins on renal pathology. Nefrologia (Engl Ed) 2021:S0211-6995(21)00146-6. [PMID: 34412931 DOI: 10.1016/j.nefro.2021.07.003] [Reference Citation Analysis]
22 Cserhalmi M, Papp A, Brandus B, Uzonyi B, Józsi M. Regulation of regulators: Role of the complement factor H-related proteins. Semin Immunol 2019;45:101341. [PMID: 31757608 DOI: 10.1016/j.smim.2019.101341] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
23 Condom P, Mansuy JM, Decramer S, Izopet J, Mengelle C. Atypical hemolytic uremic syndrome triggered by varicella infection. IDCases 2017;9:89-90. [PMID: 28725563 DOI: 10.1016/j.idcr.2017.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Zununi Vahed S, Rahbar Saadat Y, Ardalan M. Thrombotic microangiopathy during pregnancy. Microvasc Res 2021;138:104226. [PMID: 34252400 DOI: 10.1016/j.mvr.2021.104226] [Reference Citation Analysis]
25 Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 2017;92:1261-71. [PMID: 28750931 DOI: 10.1016/j.kint.2017.04.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
26 Yun JW, Oh J, Lee KO, Lee SJ, Kim JO, Kim NK, Kim JS, Koh Y, Yoon SS, Yhim HY, Jo SK, Park Y, Lee JE, Park J, Lee JW, Kim SH, Kim HJ, Oh D; Korean TTP Registry investigators., aHUS working group. Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome. Thromb Res 2020;194:45-53. [PMID: 33213850 DOI: 10.1016/j.thromres.2020.06.016] [Reference Citation Analysis]
27 Lavrishcheva YV, Yakovenko AA, Kudlai DA. [The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome]. Ter Arkh 2020;92:76-80. [PMID: 33346497 DOI: 10.26442/00403660.2020.06.000649] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Goicoechea de Jorge E, López Lera A, Bayarri-Olmos R, Yebenes H, Lopez-Trascasa M, Rodríguez de Córdoba S. Common and rare genetic variants of complement components in human disease. Mol Immunol 2018;102:42-57. [PMID: 29914697 DOI: 10.1016/j.molimm.2018.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
29 Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Front Immunol 2019;10:853. [PMID: 31118930 DOI: 10.3389/fimmu.2019.00853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
30 Pouw RB, Gómez Delgado I, López Lera A, Rodríguez de Córdoba S, Wouters D, Kuijpers TW, Sánchez-Corral P. High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B. Front Immunol 2018;9:848. [PMID: 29740447 DOI: 10.3389/fimmu.2018.00848] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]